Related Experiment Videos
Acute and chronic hypoxic pulmonary hypertension
1Dept of Respiratory Physiology, Papworth Hospital, Cambridge, UK.
The European Respiratory Journal
|September 1, 1993
Summary
Chronic hypoxia worsens pulmonary hypertension (PH) prognosis. Reduced nitric oxide (NO) production by pulmonary endothelium due to sustained hypoxia may drive PH development, offering therapeutic targets.
Area of Science:
- Pulmonary Medicine
- Cardiovascular Research
- Cellular Physiology
Background:
- Secondary pulmonary hypertension (PH) significantly worsens prognosis in patients with pulmonary disease.
- Chronic hypoxia is a primary driver of PH development, with long-term oxygen therapy (LTOT) showing potential to impede its progression.
- Hypoxia directly impacts pulmonary artery smooth muscle cells and endothelial function, involving intracellular calcium and ion transport mechanisms.
Purpose of the Study:
- To investigate the role of chronic hypoxia in the development of secondary pulmonary hypertension.
- To explore the mechanisms of endothelial adaptation to hypoxia, specifically focusing on nitric oxide (NO) production.
- To identify potential therapeutic targets for treating PH associated with chronic lung diseases.
Main Methods:
- Analysis of cellular and molecular adaptations in pulmonary endothelium under sustained hypoxic conditions.
- Investigation of nitric oxide synthase (NOS) regulation, including constitutive and inducible forms.
- Examination of potential modifications in gene transcription or translation in endothelial cells exposed to chronic hypoxia.
Main Results:
- Sustained hypoxia leads to adaptations in pulmonary endothelium, including reduced nitric oxide (NO) production.
- Impaired endothelial NO production, potentially due to decreased nitric oxide synthase activity, may contribute to secondary PH.
- Acute hypoxia causes pulmonary artery smooth muscle contraction via intracellular calcium, while relaxation involves ion transport mechanisms.
Conclusions:
- Reduced endothelial nitric oxide (NO) production is a key factor in the development of secondary pulmonary hypertension (PH) under chronic hypoxic conditions.
- Understanding the regulation of nitric oxide synthase (NOS) in response to hypoxia offers opportunities for novel therapeutic interventions.
- Further research into hypoxia-induced cellular and molecular adaptations in humans is crucial for developing new treatments for chronic obstructive lung disease (COPD) and associated PH.